Gliomas are the most common primary intracranial tumor worldwide. The maintenance of telomeres serves as an important biomarker of some subtypes of glioma. In order to investigate the biological role of RTEL1 in glioma. Relative telomere length (RTL) and RTEL1 mRNA was explored and regression analysis was performed to further examine the relationship of the RTL and the expression of RTEL1 with clinicopathological characteristics of glioma patients. We observed that high expression of RTEL1 is positively correlated with telomere length in glioma tissue, and serve as a poor prognostic factor in TERT wild-type patients. Further in vitro studies demonstrate that RTEL1 promoted proliferation, formation, migration and invasion ability of glioma cells. In addition, in vivo studies also revealed the oncogene role of RTEL1 in glioma. Further study using RNA sequence and phospho-specific antibody microarray assays identified JNK/ELK1 signaling was up-regulated by RTEL1 in glioma cells through ROS. In conclusion, our results suggested that RTEL1 promotes glioma tumorigenesis through JNK/ELK1 cascade and indicate that RTEL1 may be a prognostic biomarker in gliomas.

中文翻译：

---

RTEL1 的高表达预示着神经胶质瘤的恶化，并通过 JNK/ELK1 级联促进肿瘤发生

神经胶质瘤是全世界最常见的原发性颅内肿瘤。端粒的维持是某些神经胶质瘤亚型的重要生物标志物。为了研究RTEL1在胶质瘤中的生物学作用。探讨相对端粒长度（RTL）和RTEL1 mRNA并进行回归分析，以进一步探讨RTL和RTEL1表达与胶质瘤患者临床病理特征的关系。我们观察到RTEL1的高表达与神经胶质瘤组织中的端粒长度呈正相关，并且是TERT野生型患者的不良预后因素。进一步的体外研究表明RTEL1促进胶质瘤细胞的增殖、形成、迁移和侵袭能力。此外，体内研究还揭示了RTEL1在胶质瘤中的癌基因作用。使用 RNA 序列和磷酸化特异性抗体微阵列检测的进一步研究发现，神经胶质瘤细胞中的 RTEL1 通过 ROS 上调 JNK/ELK1 信号传导。总之，我们的结果表明 RTEL1 通过 JNK/ELK1 级联促进神经胶质瘤的发生，并表明 RTEL1 可能是神经胶质瘤的预后生物标志物。